The company also continues to give investors what they most crave. Later this year, Shire expects to start selling Intuniv, an ADHD drug that, unlike others in its category, is not considered addictive and will not be regulated as strictly by the Drug Enforcement Administration. That means patients will be able to get refills without getting a new prescription from a doctor, a time- and money-saver in today's hyperactive world.
Shire's Attention Dilemma
Second-quarter sales
of Shire drugs. Adderall XR (below), Vyvanse (right), and Daytrana treat ADHD. Generic versions of Adderall became available in April. In millions of dollars: